Delayed Obstruction With Asymptomatic Loss of Renal Function After Dextranomer/Hyaluronic Acid Copolymer (Deflux) Injection for Vesicoureteral Reflux: A Close Look at a Disturbing Outcome

Dimitri Papagiannopoulos*, Ilina Rosoklija, Earl Cheng, Elizabeth Yerkes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Dextranomer/hyaluronic acid copolymer (Deflux) first received Food and Drug Administration approval in 2001 for endoscopic injection in children with grade II-IV vesicoureteral reflux VUR. As experience has grown, Deflux has been used more liberally with encouraging results. We report 3 cases where Deflux was used in off-label fashion, resulting in delayed ureteral obstruction and loss of renal function (range 18-52 months postoperatively). We now place increased emphasis on the need for long-term follow-up after Deflux in both routine and complex cases, particularly in situations of off-label use.

Original languageEnglish (US)
Pages (from-to)63-66
Number of pages4
JournalUrology
Volume101
DOIs
StatePublished - Mar 1 2017

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Delayed Obstruction With Asymptomatic Loss of Renal Function After Dextranomer/Hyaluronic Acid Copolymer (Deflux) Injection for Vesicoureteral Reflux: A Close Look at a Disturbing Outcome'. Together they form a unique fingerprint.

Cite this